Findings

What do systematic reviews say?

20 questions · 20 findings · 2 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 35%GRADE not reported 0 · 0%Very low 0 · 0%Low 9 · 45%Moderate 3 · 15%High 1 · 5%

Immune checkpoint inhibitors vs any first‐line chemotherapy

Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 393 participants
Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 727 participants
Low

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 691 participants
Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 544 participants
Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 401 participants
Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 394 participants
Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 460 participants
Moderate

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 506 participants
Low

Sunitinib vs everolimus (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Low

Pazopanib vs placebo (targeted agent versus placebo)

Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
High

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Low

Pazopanib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 467 participants
Low